Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management After Myocardial Infarction.

Michel Accad1, Andrew D. Michaels

  • 1Division of Cardiology, Department of Medicine, University of California, San Francisco Medical Center, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143-0124, USA. andrewm@itsa.ucsf.edu

Current Treatment Options in Cardiovascular Medicine
|January 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac bridging integrator 1 gene therapy rescues chronic non-ischemic heart failure in minipigs.

NPJ Regenerative medicine·2024
Same author

Where Brain Death Is Concerned-NOT Debate BUT Action.

The Linacre quarterly·2023
Same author

Does evidence based medicine adversely affect clinical judgment?

BMJ (Clinical research ed.)·2018
Same author

How Western medicine lost its soul.

The Linacre quarterly·2016
Same author

Taking up the proposal of allocating one slot a month for a year to qualitative research.

BMJ (Clinical research ed.)·2016
Same author

Of wholes and parts: A Thomistic refutation of "Brain Death".

The Linacre quarterly·2016
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Survivors of acute myocardial infarction (MI) face significantly higher risks. Effective management involves modifying risk factors and utilizing therapies to improve prognosis and prevent future cardiovascular events.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Internal Medicine

Background:

  • Individuals surviving acute myocardial infarction (MI) exhibit a substantially increased risk of cardiovascular morbidity and mortality.
  • Management of post-MI patients focuses on modifying traditional coronary risk factors like hypertension, hyperlipidemia, tobacco use, and diabetes mellitus.
  • Pathophysiological disorders post-MI, including endothelial dysfunction, thrombosis, and plaque instability, contribute to poor prognosis.

Purpose of the Study:

  • To outline strategies for secondary prevention in patients following acute myocardial infarction.
  • To emphasize the importance of risk stratification and comprehensive patient evaluation before hospital discharge.
  • To highlight the role of pharmaceutical agents in improving outcomes after acute MI.

Related Experiment Videos

Main Methods:

  • Review of established guidelines and therapeutic options for secondary prevention post-MI.
  • Emphasis on risk stratification through diagnostic testing, including assessment of left ventricular systolic function, myocardial ischemia, and ventricular arrhythmias.
  • Discussion of available pharmaceutical agents for secondary prevention.

Main Results:

  • Modification of traditional risk factors is a cornerstone of post-MI management.
  • Aggressive risk stratification identifies high-risk patients.
  • Comprehensive pre-discharge evaluation is crucial for optimizing patient care.
  • Pharmaceutical agents such as antiplatelet agents, beta-blockers, ACE inhibitors, and statins are vital for secondary prevention.

Conclusions:

  • Secondary prevention after acute MI is critical to reduce subsequent cardiovascular events.
  • A multi-faceted approach including risk factor modification, risk stratification, and pharmacotherapy is essential.
  • Optimizing patient management post-MI improves long-term prognosis and reduces mortality.